Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
